ArticleThe oncologist2024

Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.

Hsing-Wu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.